Chlorambucil

Bone Marrow Suppression; Teratogen

  • Bone Marrow Suppression: severe
  • Carcinogen in humans
  • Mutagen, Teratogen: Probable in humans
  • Infertility associated with this drug

Monitoring data

  • Perform weekly hematological testing to determine hemoglobin, total & differential leukocyte counts, & quantitative platelet counts. Perform WBC during the first 3 to 6 weeks of therapy, at 3 or 4 days after each weekly complete blood cell counts.

Patient counseling

Package inserts

Additional information

Updated: January 2018